Details for New Drug Application (NDA): 202313
✉ Email this page to a colleague
NDA 202313 describes ADENOSINE, which is a drug marketed by Am Regent, Fresenius Kabi Usa, Gland, Gland Pharma Ltd, Hikma, Mylan Labs Ltd, Pharmobedient, Rising, Teva Pharms Usa, Wockhardt, Avet Lifesciences, Eugia Pharma, Hospira, Meitheal, and Mylan Asi, and is included in twenty-one NDAs. It is available from thirteen suppliers. Additional details are available on the ADENOSINE profile page.
The generic ingredient in ADENOSINE is adenosine. There are twenty-six drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the adenosine profile page.
The generic ingredient in ADENOSINE is adenosine. There are twenty-six drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the adenosine profile page.
Summary for 202313
| Tradename: | ADENOSINE |
| Applicant: | Avet Lifesciences |
| Ingredient: | adenosine |
| Patents: | 0 |
Pharmacology for NDA: 202313
| Mechanism of Action | Adenosine Receptor Agonists |
Medical Subject Heading (MeSH) Categories for 202313
Suppliers and Packaging for NDA: 202313
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ADENOSINE | adenosine | SOLUTION;INTRAVENOUS | 202313 | ANDA | NorthStar Rx LLC | 16714-556 | 16714-556-01 | 1 VIAL in 1 CARTON (16714-556-01) / 20 mL in 1 VIAL |
| ADENOSINE | adenosine | SOLUTION;INTRAVENOUS | 202313 | ANDA | NorthStar Rx LLC | 16714-997 | 16714-997-01 | 1 VIAL in 1 CARTON (16714-997-01) / 30 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 60MG/20ML (3MG/ML) | ||||
| Approval Date: | Sep 15, 2014 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 90MG/30ML (3MG/ML) | ||||
| Approval Date: | Sep 15, 2014 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
